Related Experiment Video

Updated: Feb 8, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

10.5K

CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas

Marcus P Watkins1, Nancy L Bartlett1

  • 1a Washington University School of Medicine , St. Louis , MO.

Expert Opinion on Investigational Drugs
|June 27, 2018
PubMed
Abstract

Insights

Anti-CD19 therapies show promise for B cell non-Hodgkin lymphoma. Chimeric antigen receptor (CAR)-T cell therapies are most promising, offering potential cures for refractory diffuse large B cell lymphoma (DLBCL).

Area of Science:

  • Oncology
  • Immunotherapy
  • Hematology

Background:

  • CD19 is widely expressed on B cell non-Hodgkin lymphoma, making it a key target for immune therapies.
  • Various anti-CD19 therapeutic strategies are under investigation for B cell malignancies.

Purpose of the Study:

  • To review the current literature on anti-CD19 therapies in clinical trials.
  • To evaluate the efficacy and challenges of different anti-CD19 approaches.

Main Methods:

  • Review of clinical trial data for monoclonal antibodies (mAb), antibody-drug conjugates (ADC), bispecific antibodies, and chimeric antigen receptor (CAR)-T cells targeting CD19.
  • Analysis of reported clinical benefits, toxicities, and development hurdles for each therapy type.

Main Results:

  • Naked anti-CD19 mAbs show limited clinical benefit in B cell lymphomas.
  • Anti-CD19 ADCs face toxicity challenges but offer durable remissions in some refractory lymphomas.
  • Bispecific T cell engagers like blinatumomab show responses in DLBCL but have neurotoxicity and administration issues.
  • CAR-T cell therapies targeting CD19 are highly promising for refractory DLBCL, with potential for significant patient benefit.

Conclusions:

  • While challenges like toxicity, production time, and cost persist, anti-CD19 therapies, particularly CAR-T cells, represent a significant advancement in treating relapsed/refractory aggressive lymphomas.
  • Continued research and development are crucial to overcome existing limitations and maximize the therapeutic potential of CD19-targeted treatments.
Keywords:
B cell lymphomaCAR-T cellsCD19antibody drug conjugatesblinatumomab

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.5K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
5.8K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Patient-centered Care01:13

Patient-centered Care

Patient-centered care involves delivering care beyond inpatient hospitalization. Reflective practice can enhance a patient-centered approach. Reflective practice is a process of reasoning that considers all aspects of the present situation, including practicalities, learning from personal practice, and consideration of patient needs. Patients appreciate care decisions made while considering their input. Involving the patient in their care provides the patient with a sense of contribution rather...
3.1K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K